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Background: Patients with systemic lupus erythematosus (SLE) have increased cardiovascular morbidity and
mortality. Although autopsy studies have documented that the heart is affected in most SLE patients, clinical
manifestations occur in less than 10%. QT dispersion is a new parameter that can be used to assess homogeneity
of cardiac repolarization and autonomic function. We compared the increase in QT dispersion in SLE patients with
high disease activity and mild or moderate disease activity.
Methods and Results: One hundred twenty-four patients with SLE were enrolled in the study. Complete history
and physical exam, ECG, echocardiography, exercise test and SLE disease activity index (SLEDAI) were recorded.
Twenty patients were excluded on the basis of our exclusion criteria. The patients were divided to two groups
based on SLEDAI: 54 in the high-score group (SLEDAI > 10) and 50 in the low-score group (SLEDAI < 10).
QT dispersion was significantly higher in high-score group (58.31 ± 18.66 vs. 47.90 ± 17.41 respectively; P < 0.004).
QT dispersion was not significantly higher in patients who had received hydroxychloroquine (54.17 ± 19.36 vs.
50.82 ± 15.96, P = 0.45) or corticosteroids (53.58 ± 19.16 vs. 50.40 + 11.59, P = 0.47). There was a statistically
significant correlation between abnormal echocardiographic findings (abnormalities of pericardial effusion,
pericarditis, pulmonary hypertension and Libman-Sacks endocarditis) and SLEADI (P < 0.004).
Conclusions: QT dispersion can be a useful, simple noninvasive method for the early detection of cardiac
involvement in SLE patients with active disease. Concerning high chance of cardiac involvement, cardiovascular
evaluation for every SLE patient with a SLEDAI higher than 10 may be recommended.
Trial registration: Clinicaltrial.gov registration NCT01031797
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Background
Systemic lupus erythematosus (SLE) is a connective tis-
sue disease characterized by the formation of autoantibo-
dies and immune complexes. Patients with SLE have
increased morbidity and mortality due to atherosclerotic
cardiovascular disease. In SLE patients, as in diabetic
patients, vascular complications may occur at a younger
age than in the general population [1]. Moreover, once
they occur, mortality may be about twice as high as in
the general population [2]. In three cohort studies [3-5]
cardiovascular mortality tended to cluster later in the
course of disease, and was equal to and possibly even
greater than that due to active lupus [6].
Cardiovascular involvement is now considered the
third leading cause of death among patients with SLE.
Autopsy studies have documented that the heart is
affected in most patients [7]. Pericarditis and premature
coronary atherosclerosis are the most prevalent cardiac
manifestations [8]. Other less frequent associations
include myocarditis, coronary arteritis, Libman-Sacks
endocarditis, constrictive pericarditis, cardiomyopathy,
congenital heart block and rhythm abnormalities. How-
ever, clinical manifestations occur in less than 10% of
SLE patients [7,9].
QT-interval parameters, in particular heart rate-cor-
rected QT interval duration, are presumed markers of
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prognostic information in clinical practice [10-14]. QT
dispersion (QTd) is defined as the inter-lead variability
in the duration of the QT interval in the 12-lead elec-
trocardiogram (ECG). This new parameter can be used
to assess the homogeneity of cardiac repolarization and
autonomic function [15]. Increased heterogeneity of
repolarization was shown in several heart diseases, and
has been associated with increased risk of ventricular
tachyarrhythmias [16]. Increased QTd has also been
shown in patients with rheumatoid arthritis, ankylosing
spondylitis and SLE [17-20].
The SLE disease activity index (SLEDAI) has been
suggested as the best means to determine disease activ-
ity [21]. An SLEDAI > 10 is indicative of high disease
activity, whereas SLEDAI equal to or below 10 indicates
mild to moderate disease activity [22]. To the best of
our knowledge there have been no studies that investi-
gated the impact of SLEDAI on QTd. We therefore
designed the present study to compare QTd in patients
with SLE without overt cardiac involvement.
Methods
Between October 2008 and March 2009, 124 patients
older than 18 years with clinical evidence of SLE accord-
ing to the revised criteria of the American College of
Rheumatology [23] and with disease duration of one year
or longer were selected from patients who were followed
at the rheumatology outpatient clinic at Namazi Hospital
in Shiraz, Iran. All patients gave written informed con-
sent to take part in the study, which was approved by the
local ethics committee. All patients fulfilled all of the
following inclusion criteria: (1) no administration of
drugs that would potentially influence QT duration
except hydroxychloroquine, (2) no history of ischemic
heart disease, congestive heart failure, atrial fibrillation,
bundle branch block or abnormal serum electrolytes, (3)
normal resting ECG and (4) a good-quality ECG record-
ing to measure the QT interval. The exclusion criteria
were: (1) moderate or severe valve disease, (2) atrial fibril-
lation and other ECG abnormalities, (3) systolic left
ventricular dysfunction (ejection fraction < 50% or left
ventricular end diastolic dimension > 5.5 mm), (4) unreli-
able identification of the end of the T wave in the ECG
and (5) known presence of cardiac disease including
hypertension, diabetes or coronary artery disease. Com-
plete history, physical examination, ECG, and transthor-
acic echocardiography were recorded in all patients.
Twenty patients with lupus were excluded from the
study on the basis of our exclusion criteria.
The patients were divided in two groups based on
modified SLEDAI (SLEDAI-2 K) scores equal to or less
than 10 (mild to moderate disease activity) or above 10
(high disease activity). The treadmill exercise test with
the Bruce protocol was used to rule out coronary artery
disease. All patients were examined and their medical
records reviewed to obtain clinical and serologic data
and to calculate the SLEDAI score. Demographic vari-
ables (age, sex, weight and height), disease duration, the
presence of atherosclerotic risk factors (smoking, hyper-
tension, dyslipidemia, diabetes, obesity and family his-
tory) and medications in current use were recorded.
Blood and 24-hour urine samples were obtained and the
following laboratory tests were done: plasma glucose,
serum total cholesterol, LDL, HDL, triglycerides, blood
cell count, ESR, CRP, anti-dsDNA antibody, antinuclear
antibody, serum complement and urine analysis.
Standard resting 12-lead ECGs were recorded in all
patients with the same equipment and response frequen-
cies at 25 mm/s paper-speed and 10 mm/mV amplitude.
QT intervals were measured in each ECG lead from the
onset of the QRS complex to the end of the T wave,
defined as a return to the T-P baseline. If U waves were
present, the patient were excluded from the study. Three
consecutive cycles in each of the 12 leads were measured.
All measurements were made by two experienced cardi-
ologists who were blind to the patient’s clinical status.
QT-interval dispersion was defined as the difference
between maximum and minimum non-rate-corrected
QT-interval duration [24]. In this study corrected QTd
was not calculated because previous studies showed that
rate correction of parameters of repolarization dispersion
i sp r o b a b l yu n n e c e s s a r ya n dm a ye v e nd i s t o r tt h ev a l u e s
and predictive usefulness of QTd [25,26].
Transthoracic echocardiographic examination was
done in all patients with a Zimence cardiac ultrasound
scanner and 2.5-3.5 MHz transducers. Color Doppler,
continuous and pulsed Doppler studies were done to
evaluate left ventricular and valvular function. The fol-
lowing parameters were recorded by a cardiologist who
was blind to the participants’ clinical data: ejection frac-
tion (EF), end systolic volume (ESV), ejection time (ET),
isovolemic relaxation time (IVRT), isovolemic contrac-
tion time (IVCT), left ventricular mass (LV mass), tissue
Doppler mitral valve parameters (A wave, S wave and E
wave) and myocardial performance index (Tei index).
All statistical analyses were done with SPSS version 15.0
software. Continuous data are reported as means and stan-
dard deviations. Because the data for QTd were distribu-
ted normally, parametric tests were used to evaluate
differences between the study groups. Means were com-
pared by analysis of variance. Spearman’s correlation rank
test was used to find correlations among parameters. A P
value below 0.05 was considered statistically significant.
Trial was registered and approved by ethical committee of
research faculty of Shiraz University of Medical Sciences.
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We studied 50 patients with a SLEDAI equal to or
below 10 (low score) and 54 patients with an SLEDAI >
10 (high score). The baseline characteristics of two
groups of the patients are shown in Table 1. There were
no significant differences with respect to age, systolic
and diastolic blood pressure, hyperlipidemia, smoking,
family history, disease duration, SLEDAI score, medica-
tions or body mass index. All patients in both groups
had normal ejection fraction (65.83 ± 9.75 vs. 64.32 ±
11.15, respectively). None of the participants had signifi-
cant valvular heart disease or other cardiac complaints.
Treadmill exercise test results were negative in all
patients.
W ef o u n dt h a tQ T dw a ss i g n i f i c a n t l yh i g h e ri nt h e
high-score group than in the low-score group (58.31 ±
18.66 vs. 47.90 ± 17.41 respectively; P <0 . 0 0 4 ) .T h e r e
was a statistically significant correlation between QTd
and cytotoxic medications (azathioprine and cyclopho-
sphamide). In patients who received cytotoxic medica-
tions, mean QTd was 61.66 ± 27.77 versus 49.59 ± 15.18
in patients who did not receive cytotoxic medications
(P = 0.002). Mean QTd in patients who had received
hydroxychloroquine was 54.17 ± 19.36 versus 50.82 ±
15.96 in patients who had not received hydroxychloro-
quine (P = 0.45). Corticosteroid treatment was not asso-
ciated with statistically significant differences in QTd
between groups. In patients who had received corticos-
teroids, mean QTd was 53.58 ± 19.16 versus 50.40 ±
11.59 in patients who had not received corticosteroids
(P = 0.47). Concerning the effect of azothioprine and
cyclophosphamide on QTd we omitted these patients
with multiple regression between two groups and new
comparison also showed significant difference in QTd
between patients with low and high score SLEDAI
(54.23 ± 17.32 Vs. 45.90 ± 18.34, P = 0.03) (Table 2).
There was no correlation between the QTd and baseline
characteristics including disease duration, ESR and the
presence of any of the diagnostic criteria for SLE. There
was no correlation between EF (%), ESV (mL), LV mass
(g), IVRT (m/s), IVCT (m/s), tissue Doppler findings in
the mitral valve (E, A and S waves), Tie index or SLEDAI
(Table 2). However, a significant correlation was found
between abnormal echocardiographic findings (including
abnormalities in pericardial effusion, pericarditis, pul-
monary hypertension and Libman-Sacks endocarditis)
and SLEADI. Patients with normal echocardiographic
findings had a SLEADI of 11.6 versus 19.13 in patients
with abnormal findings (P < 0.004).
Discussion
Increased QTd has been shown to be an important
prognostic factor in several cardiovascular conditions
such as coronary artery disease, congestive heart failure
and cardiomyopathies [27-31]. Moreover, increased QTd
has been documented in several rheumatic diseases
[17-19,32] and SLE [20]. To the best of our knowledge,
this is the first study to compare QTd in SLE patients
with high and low disease activity scores.
Cardiac involvement is the third leading cause of death
among patients with SLE. Autopsy studies have docu-
mented that the heart is affected in most patients [20].
Pericarditis and premature coronary artery disease are
the most common presentations, and other rare associa-
tions include myocarditis, coronary arteritis, Libman-
Sacks endocarditis, constrictive pericarditis, cardiomyo-
pathy, congenital heart block and rhythm abnormalities
[20,32]. Myocardial involvement can be seen in SLE
patients even in the absence of clinical cardiac manifesta-
tions. Previous studies with Tc-99 m sestamibi
Table 1 Baseline characteristics of two groups of SLE patients with high score and low score




Age (years) 33.88 ± 11.34 35.32 ± 10.8
Sex (Male:Female) 3: 51 6: 44
BMI(kg/m2) 23.36 ± 4.69 24 ± 4.34
Systolic blood pressure(mmhg) 116.48 ± 12.76 117.60 ± 9.38
Diastolic blood pressure(mmhg) 77.87 ± 8.4 79.20 ± 5.2
Duration of disease(year) 6.64 ± 3.96 5.2 ± 3.87
Left ventricular ejection fraction 64.32 ± 11.15 65.83 ± 9.75
Hydroxychloroquine 44(42%) 37(34%)
Prednisolone 52(50%) 43(41%)
Cytotoxic drugs 18(17.3%) 14(13.5%)
Systemic Lupus Erythematous Disease Activity Index (SLEDAI) 54(51.92%) 50(48.07)
*Values are means (standard deviation) or absolute numbers (proportions)
*All have no significant differences with non significant P value except SLEDAI which is significantly different in two groups (P value < 0.004)
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tomography (SPECT) showed a high incidence of myo-
cardial perfusion abnormalities in asymptomatic lupus
patients without any clinical signs of cardiac involvement
[33-35]. Schillaci et al. found that eight patients with
positive SPECT findings had normal epicardial coronary
vessels documented with coronary angiography [32]. In
patients without clinical cardiac manifestations, these
perfusion defects were probably due to the primary
immunological damage and small focal cardiofibrosis in
this autoimmune disease. The areas of myocardial fibro-
sis in SLE may disrupt the course of ventricular repolari-
zation and lead to increased dispersion of recovery times
throughout the ventricle.
We found that QTd was significantly higher in SLE
patients with high disease activity than in patients with
mild to moderate disease activity. Because QTd provides
useful information on the heterogeneity of ventricular
repolarization, increased QTd in the present study may
reflect silent myocardial involvement in SLE patients
with high activity disease. Therefore, QTd may be a use-
ful simple marker of subclinical myocardial involvement
in SLE patients with high disease activity compared to
mild to moderate disease activity. The significance of
this finding is strengthened by the consideration that
hydroxychloroquine, a cytotoxic agent commonly used
in SLE patients, cannot in itself explain the increase in
QTd. Increased QTd in patients with SLE may be a
marker of silent myocardial involvement with its own
potentially ominous prognosis. In addition, it can be
used as a marker of disease activity or even as a simple
way to diagnose SLE itself when other clues are insuffi-
cient. Whether increased QTd in patient with SLE pre-
dicts poorer clinical outcomes or mandates any special
treatments warrants further study.
Conclusions
QT dispersion was significantly increased in SLE
patients with high disease activity compared to patients
with low disease activity. Our findings suggest that
increased QTd is a potentially useful, simple, noninva-
sive method for the early detection of subclinical cardiac
involvement in patients with high-activity SLE. We sug-
gest that SLE patients with a SLEDAI > 10 may be con-
sidered for referral for cardiovascular evaluation.
Study limitation
Small number of our patients, lack of long term moni-
toring to detect possible arrhythmia due to long QT dis-
persion which is an index of arrhythmia susceptibility in
high score groups are our study limitations. We did not
check anti Ro antibody, and concerning its possible role
on prolongation of QT dispersion further study to clar-
ify this effect may be needed.
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Table 2 Comparison of echocardiographic parameters and QTd between two groups (high score and low score) of SLE
patients
Low score High score P value
Left ventricular ejection fraction 9.7583 ± .65 11.15 ± 64.32 0.46
ESV (cc) 8.56 ± 25.57 12.02 ± 27.25 0.41
Left ventricular mass(gr) 55.58 ± 160.08 54.11 ± 140.66 0.33
Ewave (cm) 4.72 ± 18.24 4.81 ± 19.94 0.07
Awave (cm) 4.22 ± 14.54 10.16 ± 16.26 0.26
Swave (cm) 3.53 ± 15.30 4.21 ± 15.74 0.56
IVRT (m/sec)* 18.90 ± 77.24 21.10 ± 84.74 0.06
IVCT (m/sec)* 22.23 ± 70.20 22.27 ± 70.59 0.93
Tei index 0.142 ± 0.581 0.218 ± 0.618 0.30
QTd 58.31 ± 18.66 vs. r 47.90 ± 17.41 < 0.004
QTd
(in those without use of cyclophosphamide and azothioprine drugs)
54.23 ± 17.32 45.90 ± 18.34 0.03
*- ESV End systolic volume, IVRT Isovolumic relaxation time, IVCT Isovolumic contraction time
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